HYPERION DEFI, INC.
Current- Director 2022 to present
Executive record
Alpha ID: alpha:person:michael-rowe-2Version: public-0As of: 2026-09-28
Michael Rowe has served as Chief Executive Officer and Acting Chair of the Board since August 2022. He previously served as Corporate Vice President and Chief Operating Officer of the Company. He brings extensive pharmaceutical and medical device commercialization experience from his roles at Aerie Pharmaceuticals, Allergan, and other companies.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
sec filing · Source published: Mar 23, 2026 · Retrieved: May 16, 2026
sec filing · Source published: Jul 24, 2025 · Retrieved: May 16, 2026
sec proxy · Source published: Jul 24, 2025 · Retrieved: Apr 28, 2026
public source · Source published: Date unavailable · Retrieved: Date unavailable
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-28